KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

被引：0
|
作者：
Kramer, Gero
Shore, Neal D.
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
Yu, Evan Y.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[3] St Vincents Hosp Sydney, Sydney, NSW, Australia
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS215
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
  • [22] KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    Todenhoefer, T.
    Piulats, J. M.
    Ferrario, C.
    Linch, M. D.
    Stoeckle, M.
    Laguerre, B.
    Arranz, J. A.
    Fong, P. C. C.
    Berry, W. R.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A. M.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    De Bono, J. S.
    Yu, E. Y.
    EUROPEAN UROLOGY, 2022, 81 : S789 - S790
  • [23] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [24] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Yu, Evan Y.
    Kolinsky, Michael P.
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Appleman, Leonard J.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    Bogemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Linch, Mark
    Sridhar, Srikala
    Conter, Henry J.
    Laguerre, Brigitte
    Massard, Christophe
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian H.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
  • [25] Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
    Yu, Evan Y.
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Conter, Henry J.
    Laguerre, Brigitte
    Fong, Peter C. C.
    Ferrario, Cristiano
    Todenhofer, Tilman
    Gravis, Gwenaelle
    Piulats, Josep M.
    Emmenegger, Urban
    Shore, Neal D.
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian H.
    Schloss, Charles
    Appleman, Leonard J.
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 509 - 518
  • [26] PHASE 1B/2 KEYNOTE-365 COHORT I: PLATINUM-CONTAINING CHEMOTHERAPY ALONE OR IN COMBINATION WITH PEMBROLIZUMAB FOR TREATMENT-EMERGENT NEUROENDOCRINE PROSTATE CARCINOMA
    De Bono, Johann
    Shore, Neal
    Kramer, Gero
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A448 - A448
  • [27] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Phase Ib/II-Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) Phase Ib/II-Study of Pembrolizumab (MK-3475) Combination Therapies in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
    Rexer, H.
    Wuelfing, C.
    Retz, M.
    UROLOGE, 2018, 57 (01): : 120 - 121
  • [29] Multicohort Phase 1b/2 Study of Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Updated Results From KEYNOTE 365 Cohorts A-C
    Gurney, Howard
    Fong, Peter C. C.
    Joshua, Anthony M.
    Retz, Margitta
    Tafreshi, Ali
    Shore, Neal D.
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Berry, William R.
    Kolinsky, Michael P.
    Sridhar, Srikala S.
    Conter, Henry J.
    Todenhofer, Tilman
    Appleman, Leonard J.
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    de Bono, Johann S.
    Yu, Evan Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 59 - 60
  • [30] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345